Transfuse Betibeglogene in Periph Vein, Perc, New Tech 8

This code represents the administration of betibeglogene autotemcel, a gene therapy product, directly into a patient's peripheral vein. This procedure is performed to introduce genetically modified cells into the bloodstream for therapeutic purposes. It is considered a novel technology, falling under New Technology Group 8.

This code is used when a patient receives betibeglogene autotemcel via a peripheral intravenous infusion. This typically occurs in the treatment of transfusion-dependent beta-thalassemia, where the gene therapy aims to enable the patient's body to produce functional hemoglobin. The administration must be via a peripheral vein, not a central line.

• Ensure documentation specifies "peripheral vein" for the infusion site.
• Verify the substance administered is specifically betibeglogene autotemcel.
• Do not use for administration of other gene therapies or blood products.